479 related articles for article (PubMed ID: 21246383)
1. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts.
Tamori A; Koike T; Goto H; Wakitani S; Tada M; Morikawa H; Enomoto M; Inaba M; Nakatani T; Hino M; Kawada N
J Gastroenterol; 2011 Apr; 46(4):556-64. PubMed ID: 21246383
[TBL] [Abstract][Full Text] [Related]
2. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
[TBL] [Abstract][Full Text] [Related]
3. Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs.
Tan J; Zhou J; Zhao P; Wei J
Clin Rheumatol; 2012 Aug; 31(8):1169-75. PubMed ID: 22544263
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy.
Lee YH; Bae SC; Song GG
Clin Exp Rheumatol; 2013; 31(1):118-21. PubMed ID: 23111095
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs.
Lee YH; Bae SC; Song GG
Int J Rheum Dis; 2013 Oct; 16(5):527-31. PubMed ID: 24164839
[TBL] [Abstract][Full Text] [Related]
6. Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor-α therapy.
Fidan S; Capkın E; Arıca DA; Durak S; Okatan IE
Int J Rheum Dis; 2021 Feb; 24(2):254-259. PubMed ID: 33244900
[TBL] [Abstract][Full Text] [Related]
7. Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs.
Watanabe T; Fukae J; Fukaya S; Sawamukai N; Isobe M; Matsuhashi M; Shimizu M; Akikawa K; Tanimura K; Atsumi T; Koike T
Int J Rheum Dis; 2019 Apr; 22(4):574-582. PubMed ID: 30338649
[TBL] [Abstract][Full Text] [Related]
8. Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study.
Varisco V; Viganò M; Batticciotto A; Lampertico P; Marchesoni A; Gibertini P; Pellerito R; Rovera G; Caporali R; Todoerti M; Covelli M; Notarnicola A; Atzeni F; Sarzi-Puttini P
J Rheumatol; 2016 May; 43(5):869-74. PubMed ID: 26879359
[TBL] [Abstract][Full Text] [Related]
9. Safety of Tocilizumab in Rheumatoid Arthritis Patients with Resolved Hepatitis B Virus Infection: Data from Real-World Experience.
Ahn SS; Jung SM; Song JJ; Park YB; Park JY; Lee SW
Yonsei Med J; 2018 May; 59(3):452-456. PubMed ID: 29611409
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis.
Harigai M; Winthrop K; Takeuchi T; Hsieh TY; Chen YM; Smolen JS; Burmester G; Walls C; Wu WS; Dickson C; Liao R; Genovese MC
RMD Open; 2020 Feb; 6(1):. PubMed ID: 32098857
[TBL] [Abstract][Full Text] [Related]
11. Risk stratification and clinical course of hepatitis B virus reactivation in rheumatoid arthritis patients with resolved infection: final report of a multicenter prospective observational study at Japanese Red Cross Hospital.
Fukuda W; Hanyu T; Katayama M; Mizuki S; Okada A; Miyata M; Handa Y; Hayashi M; Koyama Y; Arii K; Kitaori T; Hagiyama H; Urushidani Y; Yamasaki T; Ikeno Y; Suzuki T; Omoto A; Sugitani T; Morita S; Inokuma S
Arthritis Res Ther; 2019 Nov; 21(1):255. PubMed ID: 31779676
[TBL] [Abstract][Full Text] [Related]
12. Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Tocilizumab-Containing Treatment.
Kuo MH; Tseng CW; Lu MC; Tung CH; Tseng KC; Huang KY; Lee CH; Lai NS
Dig Dis Sci; 2021 Nov; 66(11):4026-4034. PubMed ID: 33387124
[TBL] [Abstract][Full Text] [Related]
13. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib.
Wang ST; Tseng CW; Hsu CW; Tung CH; Huang KY; Lu MC; Lai NS
Int J Rheum Dis; 2021 Nov; 24(11):1362-1369. PubMed ID: 34506078
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Biologics Treatment.
Chen MH; Chen MH; Liu CY; Tsai CY; Huang DF; Lin HY; Lee MH; Huang YH
J Infect Dis; 2017 Feb; 215(4):566-573. PubMed ID: 28011918
[TBL] [Abstract][Full Text] [Related]
15. No detection of occult HBV-DNA in patients with various rheumatic diseases treated with anti-TNF agents: a two-year prospective study.
Giardina AR; Ferraro D; Ciccia F; Ferrante A; Di Stefano R; Craxì A; Triolo G
Clin Exp Rheumatol; 2013; 31(1):25-30. PubMed ID: 22935442
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience.
Papadopoulos N; Deutsch M; Manolakopoulos S; Bitsi C; Michalakeas H; Poulakidas H; Tsironi E; Giannouli S; Papatheodoridis GV; Koskinas J; Pectasides D
Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):56-60. PubMed ID: 27669175
[TBL] [Abstract][Full Text] [Related]
17. Incidence of Hepatitis B Virus Reactivation and Hepatotoxicity in Patients Receiving Long-term Treatment With Tumor Necrosis Factor Antagonists.
Pauly MP; Tucker LY; Szpakowski JL; Ready JB; Baer D; Hwang J; Lok AS
Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1964-1973.e1. PubMed ID: 29702293
[TBL] [Abstract][Full Text] [Related]
18. Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs.
Nakamura J; Nagashima T; Nagatani K; Yoshio T; Iwamoto M; Minota S
Int J Rheum Dis; 2016 May; 19(5):470-5. PubMed ID: 24698305
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy.
Su YC; Lin PC; Yu HC; Wu CC
Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):925-929. PubMed ID: 29621049
[TBL] [Abstract][Full Text] [Related]
20. Lack of hepatitis B virus reactivation after anti-tumour necrosis factor treatment in potential occult carriers with chronic inflammatory arthropathies.
Biondo MI; Germano V; Pietrosanti M; Canzoni M; Marignani M; Stroffolini T; Salemi S; D'Amelio R
Eur J Intern Med; 2014 Jun; 25(5):482-4. PubMed ID: 24495663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]